Peptides for healing, injury and recovery, ranked by human evidence

Peptides studied for tendon, ligament, gut and tissue repair. A few are approved for bone or specific conditions; most are investigational or research-only, with the strongest human evidence concentrated in a handful. They are ranked by an evidence score that weighs the grade of the evidence, the human trials counted in PubMed, and regulatory status — shown in the columns so any rank can be checked. A high score means a peptide is well studied and often approved for something, not that it is right, safe or legal for this goal. Nothing here is medical advice, and Grey Peptides sells nothing and links to no vendor. See all goals or the plainer browse by goal map.

Evidence grade

Regulatory status

Search name

Has a human trial on this page

30 peptides · sorted by evidence score (click a column to re-sort)

Peptide	Grade	Human studies	RCTs	Max trial phase	Regulatory	Dose	Score
Abaloparatide	High	277	32	Phase 4	FDA approved	subcutaneous →	100
Difelikefalin	High	78	13	Phase 3	FDA approved	intravenous →	100
Palopegteriparatide	High	34	10	Phase 3	FDA approved	subcutaneous →	100
Calcitonin	High	24,870	1,028	Phase 4	FDA approved	intranasal or subcutaneous →	90
Teriparatide	High	1,424	108	Phase 4	FDA approved	subcutaneous →	90
Linaclotide	High	419	47	Phase 4	FDA approved	oral →	90
Polaprezinc	High	141	31	Phase 4	Approved abroad	oral →	90
Trafermin	High	110	12	Phase 3	Approved abroad	topical spray →	90
Plecanatide	High	97	11	Phase 3	FDA approved	oral →	90
Parathyroid hormone (1-84)	High	725	80	Phase 4	Discontinued	subcutaneous →	85
Pexiganan	High	60	1	Phase 3	Discontinued	topical →	75
Omiganan	High	35	5	Phase 3	Discontinued	—	75
Elcatonin	Medium	82	15	—	Approved abroad	intramuscular →	70
Parathyroid hormone-related protein	Medium	2,911	10	Phase 4	Research only	subcutaneous →	65
Thymosin β4	Medium	595	8	Phase 2	In trials	—	60
Larazotide	Medium	72	6	Phase 3	In trials	oral →	60
ARA-290	Medium	41	4	Phase 2	In trials	subcutaneous →	60
Histatin	Medium	671	26	—	Research only	—	55
GHK-Cu	Medium	67	3	Phase 4	Research only	—	55
Rusalatide	Low	23	1	Phase 2	Approved abroad	topical (to the ulcer) →	50
Osteocalcin	Low	12,534	1,211	Phase 4	Research only	—	45
KR-12	Medium	42	0	—	Research only	—	45
FK-13	Medium	33	0	—	Research only	—	45
Aclerastide	Low	1	1	Phase 3	Discontinued	topical →	45
Dolcanatide	Low	4	0	Phase 2	Approved abroad	oral →	40
LL-37	Low	2,821	56	Phase 3	Research only	—	35
BPC-157	Low	54	0	Phase 2	Research only	—	25
Osteogenic growth peptide	Low	47	0	Phase 2	Research only	—	25
KPV	Low	45	0	—	Research only	—	25
TB-500	Low	25	0	Phase 2	Research only	—	25

Other goals: Weight loss and metabolism · Skin and hair · Focus, mood and the brain · Growth hormone and body composition · Heart and circulation · Sexual and reproductive health · Longevity and cell health · Immune defence and infection · Diagnostic and research tools · In development

How the evidence score works

Evidence score (0-100), a transparent ranking aid, not a verdict. grade: high=60, medium=40, low=20, ungraded=0. Human trial: an on-site read-and-cited randomized or clinical trial = +15, else any PubMed human-indexed record = +5, else 0. RCT literature: PubMed lists >=1 randomized controlled trial = +10. Regulatory: FDA-approved = +15, in trials / approved-abroad / in development = +5, else 0. Every component is stored on each record so the number can be re-derived; volume and grade are shown together so neither misleads.

“Human studies” and “RCTs” are PubMed record counts for the peptide (read 2026-11-07 from the counts behind the Evidence Explorer); a count is how much research exists and of what kind, never proof a peptide works. “Grade” is our editorial reading of the evidence — see how we grade evidence. The “Dose” column links to the entry for each peptide that carries a dose from a regulator’s label or a published human study — where the amount is shown with its source; the amount is never reprinted here without that source, and many research peptides have no human dose, shown as —. Of 660 peptides, 607 have at least one human-indexed PubMed record, 324 cite a human trial on their page, 124 are FDA-approved, and 271 carry a sourced dose.